Robert W. Baird & Co. Incorporated on Ascendis Pharma
Thesis
Baird initiated a position in Ascendis Pharma as part of an increase in exposure to commercial-stage therapeutics companies with promising growth potential. The company's proprietary TransCon drug platform has already produced three drugs targeting rare endocrine diseases. Baird sees the established platform and commercial-stage portfolio as providing attractive growth potential.
“Ascendis Pharma has a proprietary drug platform called TransCon that has led to three drugs for rare endocrine diseases”